Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.

@article{Fox2000UsingSR,
  title={Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.},
  author={Nick C. Fox and Simon Cousens and Rachael I. Scahill and Richard J Harvey and Martin Rossor},
  journal={Archives of neurology},
  year={2000},
  volume={57 3},
  pages={339-44}
}
OBJECTIVE To evaluate the rate of brain atrophy calculated from serial magnetic resonance imaging (MRI) registration as a surrogate marker of disease progression for use in clinical trials in Alzheimer disease (AD). METHODS Eighteen patients with mild to moderate AD and 18 age-matched normal controls underwent 2 MRI brain scans separated by a 12-month interval. Each individual's later scan was registered to their first scan, and the volume of cerebral tissue loss calculated directly from the… CONTINUE READING
Highly Influential
This paper has highly influenced 18 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 167 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease

  • BJ Corey, R Anand, J. Veach
  • Int J Geriatr Psychopharmacol
  • 1998

Similar Papers

Loading similar papers…